Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Protara Therapeutics (TARA) Interest Expenses (2016 - 2019)

Protara Therapeutics' Interest Expenses history spans 7 years, with the latest figure at $59000.0 for Q4 2019.

  • Quarterly Interest Expenses fell 65.09% to $59000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $59000.0 through Dec 2019, down 65.09% year-over-year, with the annual reading at $59000.0 for FY2019, 65.09% down from the prior year.
  • Interest Expenses came in at $59000.0 for Q4 2019, down from $169000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $52.2 million in Q4 2015 to a low of $59000.0 in Q4 2019.
  • The 5-year median for Interest Expenses is $600000.0 (2017), against an average of $8.7 million.
  • Year-over-year, Interest Expenses surged 401700.0% in 2015 and then plummeted 99.39% in 2016.
  • Protara Therapeutics' Interest Expenses stood at $52.2 million in 2015, then tumbled by 99.39% to $321000.0 in 2016, then skyrocketed by 2064.8% to $6.9 million in 2017, then tumbled by 97.57% to $169000.0 in 2018, then tumbled by 65.09% to $59000.0 in 2019.
  • Per Business Quant, the three most recent readings for TARA's Interest Expenses are $59000.0 (Q4 2019), $169000.0 (Q4 2018), and $6.9 million (Q4 2017).